@article{44685da0addc4ea3a365850269771746,
title = "Circulating endocannabinoids and affect regulation in human subjects",
abstract = "The endocannabinoid (EC) system influences a wide variety of neurobiological processes including affect and emotionality as well as other neuropsychiatric functions. In this study we examined the relationship of circulating endocannabinoids [anandamide (AEA) and 2-arachidonoylglycerol (2-AG)] with affect and emotionality in 175 individuals with (n = 115) and without (n = 60) mood, anxiety, and/or personality disorders. Circulating AEA levels displayed a modest, though statistically significant, inverse relationship with a composite measure of affect regulation (β = − 0.264, p = 0.009), due to its relationship with affect intensity (β = − 0.225, p = 0.021) across all study participants. Neither AEA nor 2-AG level differed as a function of any syndromal/personality disorder and neither correlated significantly with state depression or state anxiety scores. These data suggest that circulating levels endocannabinoids may play a role in emotionality across individuals regardless of defined psychiatric disorder.",
keywords = "Affect regulation, Anxiety, Depression, Endocannabinoids",
author = "Coccaro, {Emil F.} and Hill, {Matthew N.} and Lauren Robinson and Lee, {Royce J.}",
note = "Funding Information: RO1 MH60836, RO1 MH63262, RO1 MH66984, RO1 MH80108 (Dr. Coccaro). MNH is a Tier II Canada Research Chair and is supported by operating funds from the Canadian Institutes of Health Research (CIHR). The authors would like to thank the Southern Alberta Mass Spectrometry Centre, located in and supported by the Cumming School of Medicine, University of Calgary, for their services in targeted liquid chromatography tandem mass spectrometry. Funding Information: The role of funding sources [National Institute of Mental Health: RO1 MH60836, RO1 MH63262, RO1 MH66984, RO1 MH80108 (Dr. Coccaro) and Canadian Institutes of Health Research (CIHR)] was to cover the cost of data collection and assays. Funding sources had no role in the design, analysis, or interpretation of the data. Funding Information: This work was supported in part by grants from the National Institute of Mental Health: Funding Information: Dr. Coccaro reports being on the Scientific Advisory Board of Azevan Pharmaceuticals and is a consultant to Avanir Pharmaceuticals, Inc.; Dr. Hill reports having received consulting fees from Pfizer International and receiving consulting fees and unrestricted operating funds from GW Pharmaceuticals; Dr. Lee reports being the recipient of a research grant from Azevan Pharmaceuticals, and from Avanir Pharmaceuticals; and Dr. Robinson reports no biomedical financial interests or potential conflicts of interest. Publisher Copyright: {\textcopyright} 2018 Elsevier Ltd",
year = "2018",
month = jun,
doi = "10.1016/j.psyneuen.2018.03.009",
language = "English (US)",
volume = "92",
pages = "66--71",
journal = "Psychoneuroendocrinology",
issn = "0306-4530",
publisher = "Elsevier Limited",
}
